1,000-Patient study to see if ancient herbal medicine slows lung scarring
NCT ID NCT07162870
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will follow 1,000 people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and breathing problems. Researchers will compare those who take traditional Chinese medicine (TCM) for at least three months a year to those who do not. The goal is to see if TCM reduces flare-ups and slows disease progression, and to identify which patients benefit most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Traditional Chinese medicine (herbal formulas taken for at least 3 months per year)
What this could lead to
If successful, this study could help doctors identify which IPF patients are most likely to benefit from traditional Chinese medicine, and guide more personalized treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Differences between groups may be due to other factors, and results may not apply to all IPF patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Henan University of Chinese Medicine
Zhengzhou, Henan, 450000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••